# Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.

> **NCT05946460** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Guangzhou Medical University** · enrollment: 22 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Aumolertinib

## Key facts

- **NCT ID:** NCT05946460
- **Lead sponsor:** The First Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-15
- **Primary completion:** 2025-07-10
- **Final completion:** 2025-07-10
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2024-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05946460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05946460, "Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05946460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*